Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Northwest Biotherapeutics (NWBO) EBIT Margin: 2010-2025

Historic EBIT Margin for Northwest Biotherapeutics (NWBO) over the last 16 years, with Sep 2025 value amounting to -7,160.00%.

  • Northwest Biotherapeutics' EBIT Margin fell 301406.00% to -7,160.00% in Q3 2025 from the same period last year, while for Sep 2025 it was -6,927.32%, marking a year-over-year decrease of 297049.00%. This contributed to the annual value of -4,812.45% for FY2024, which is 193936.00% down from last year.
  • Latest data reveals that Northwest Biotherapeutics reported EBIT Margin of -7,160.00% as of Q3 2025, which was up 36.53% from -11,281.68% recorded in Q2 2025.
  • Northwest Biotherapeutics' EBIT Margin's 5-year high stood at 925.93% during Q4 2021, with a 5-year trough of -11,281.68% in Q2 2025.
  • For the 3-year period, Northwest Biotherapeutics' EBIT Margin averaged around -5,383.26%, with its median value being -4,616.27% (2025).
  • In the last 5 years, Northwest Biotherapeutics' EBIT Margin surged by 37,381,755bps in 2021 and then plummeted by 785,737bps in 2025.
  • Quarterly analysis of 5 years shows Northwest Biotherapeutics' EBIT Margin stood at 925.93% in 2021, then crashed by 397,082bps to -3,044.89% in 2022, then tumbled by 35,781bps to -3,402.70% in 2023, then crashed by 460,553bps to -8,008.23% in 2024, then tumbled by 301,406bps to -7,160.00% in 2025.
  • Its EBIT Margin stands at -7,160.00% for Q3 2025, versus -11,281.68% for Q2 2025 and -4,616.27% for Q1 2025.